tradingkey.logo

Kailera Therapeutics & Hengrui Pharma Report Positive Topline Data From Phase 2 Obesity Trial Of Oral Ribupatide

ReutersFeb 10, 2026 12:13 PM

- KAILERA THERAPEUTICS:

  • KAILERA THERAPEUTICS: CO, HENGRUI PHARMA REPORT POSITIVE TOPLINE DATA FROM PHASE 2 OBESITY TRIAL OF ORAL RIBUPATIDE

  • KAILERA THERAPEUTICS: MEAN WEIGHT LOSS OF UP TO 12.1% WITH NO OBSERVED PLATEAU AT 26 WEEKS IN PHASE 2 TRIAL IN CHINA WITH ORAL RIBUPATIDE

  • KAILERA THERAPEUTICS: HENGRUI TO TEST ORAL RIBUPATIDE IN PHASE 3 TRIAL IN CHINA; CO PLANS TO INITIATE GLOBAL PHASE 2 CLINICAL TRIAL IN 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI